GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook

Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential.

Analyst Commentary

Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.

Bullish Takeaways

Bullish analysts highlight that recent acquisitions and the addition of assets like petosemtamab support a broader pipeline, which they see as helpful for sustaining the business beyond future royalty declines such as Darzalex after 2029.
Several firms maintain Buy ratings with price targets around US$40 to US$41.50. They frame Genmab as having enough upcoming clinical and regulatory milestones in 2026 to support execution on growth plans.
Model updates after the 2025 earnings report are framed by bullish analysts as reinforcing their constructive stance on earnings power, which then feeds into their valuation work.
Some research points to a "catalyst rich" 2026, with both Epkinly and newer assets expected to provide key readouts that, in their models, could help underpin long term growth narratives.

Bearish Takeaways

Bearish analysts trim price targets, for example to US$40 from US$45, explicitly tying the move to lowered near term Epkinly estimates. This then feeds into more cautious revenue and earnings projections.
More neutral research, such as Equal Weight ratings with US$34 price targets, reflects a view that while the Merus acquisition and Epkinly updates are important, execution risk around 2026 catalysts and integration of new assets keeps valuations in check.
The miss on overall survival in a Phase 3 trial, flagged by some research, adds another layer of clinical risk that investors need to weigh against 2026 data readouts, even if some analysts still express optimism for future results.
Across coverage, the split between Buy and more neutral ratings shows ongoing debate about how quickly Epkinly and pipeline assets can translate into earnings and whether current P/E expectations fully capture execution and clinical risk.

What's in the News

Genmab issued 2026 guidance, projecting revenue of US$4.1b to US$4.4b, compared with US$3.7b in 2025, and an operating profit range of US$0.9b to US$1.4b, with management citing contributions from royalties, net product sales and collaboration revenue.
New data for rinatabart sesutecan (Rina S) in combination with bevacizumab in advanced ovarian cancer showed a safety profile consistent with the individual drugs, with manageable treatment emergent adverse events and no new safety signals reported, from the RAINFOL 01 Phase 1/2 study presented at the 2026 Society of Gynecologic Oncology meeting.
Rina S is moving through a broad clinical program, including multiple Phase 3 RAINFOL studies in ovarian and endometrial cancers and a Phase 2 trial in non small cell lung cancer, targeting cancers described as having unmet need.
Topline Phase 3 EPCORE DLBCL 1 data for epcoritamab monotherapy in relapsed or refractory diffuse large B cell lymphoma showed improvement in progression free survival versus standard regimens. Overall survival did not reach statistical significance, and Genmab and AbbVie plan to discuss next steps with regulators.
Reuters reported that drugmakers, including Genmab, are using AI to help advance work on clinical trials and regulatory submissions, which may influence how you think about the company’s development and approval processes over time (Reuters).

Valuation Changes

Fair Value: DKK 2,233.38 is slightly lower than the prior DKK 2,237.63, reflecting modestly updated assumptions.
Discount Rate: The model discount rate has risen slightly from 5.82% to 5.85%, indicating a marginally higher required return.
Revenue Growth: Forecast revenue growth has moved up from 18.64% to 19.49%, suggesting slightly stronger expected top line expansion in the model.
Net Profit Margin: The assumed net profit margin has shifted from 29.42% to 28.28%, indicating a more conservative view on profitability.
Future P/E: The future P/E multiple has increased from 12.71x to 13.04x, indicating a modestly higher valuation multiple applied to projected earnings.

12 views

Key Takeaways

Robust pipeline, global expansion, and independent product launches position Genmab for significant growth and improved competitive standing in targeted biologic therapies.
Strong recurring royalties and disciplined investment support stable cash flow, financial flexibility, and sustainable long-term earnings growth with diversified portfolio risk.
Genmab faces pressure from drug pricing, dependency on major partnerships, regulatory and pipeline risks, and intensifying competition threatening future growth and profitability.

Catalysts

About Genmab

A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.What are the underlying business or industry changes driving this perspective?

Strong late-stage pipeline progress-including positive Phase III results for epcoritamab (EPKINLY) and expansion of Rina-S programs-positions Genmab to benefit from the growing global burden of cancer and rising demand for innovative biologic therapies, supporting significant future revenue and earnings growth.
Continued advancement of innovative antibody and bispecific therapeutics leverages breakthroughs in precision medicine, likely increasing Genmab's competitive positioning and addressable market as healthcare systems prioritize targeted, personalized treatments, positively impacting long-term revenue trajectories.
Rapid international expansion and successful independent launches of EPKINLY and Tivdak (including in Europe and Japan) demonstrate Genmab's ability to capture a greater share of global healthcare spending, widening its revenue base and ultimately supporting higher operating margins as scale efficiencies improve.
Strong recurring royalty streams from established partnered products (such as DARZALEX) and a rising contribution from wholly owned product sales underpin stable, predictable cash flows, providing financial flexibility for pipeline investment and margin expansion.
Ongoing investment in commercialization infrastructure and disciplined R&D execution-backed by a robust cash position-set the stage for sustainable earnings growth as new products are introduced, markets expand, and portfolio risk becomes increasingly diversified.

Genmab Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Genmab's revenue will grow by 19.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 25.9% today to 28.3% in 3 years time.
Analysts expect earnings to reach $1.8 billion (and earnings per share of $28.21) by about April 2029, up from $963.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.5 billion in earnings, and the most bearish expecting $1.1 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 13.2x on those 2029 earnings, down from 18.5x today. This future PE is greater than the current PE for the GB Biotechs industry at 11.2x.
Analysts expect the number of shares outstanding to decline by 2.72% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 5.85%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Intensifying drug pricing pressures and tightened healthcare budgets in key markets (US, Europe) could constrain Genmab's pricing power and reimbursement access, which may slow future revenue and net margin growth despite the company's recent commercialization successes and strong sales momentum.
Overreliance on significant partnered assets, particularly DARZALEX (a key royalty driver), exposes Genmab to risks of renegotiated terms, royalty rate reductions, or even loss of rights, potentially leading to revenue volatility or future earnings declines as peak sales plateau or biosimilar competition emerges.
Regulatory risks-including heightened scrutiny, changing FDA review processes (noted market "chaos" at the FDA), and the possibility of delayed or denied approvals-pose a threat to pipeline advancement timelines, which could delay commercialization and revenue recognition for late-stage assets like Rina-S and EPKINLY in new indications.
Pipeline execution risk remains, as seen with the discontinuation of at least two HexaBody platform assets in 2025; if other pipeline programs also fail to differentiate or meet clinical endpoints, Genmab could face reduced R&D ROI, impairments, or stunted long-term growth in revenue and earnings.
Growing competition-both from other CD20 bispecifics (e.g., Roche's mosunetuzumab) and from emerging modalities like ADCs and next-generation immunotherapies-could erode Genmab's first-mover advantages, limit future market share, and pressure both future revenue trajectories and sustainable net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of DKK2233.38 for Genmab based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK3041.0, and the most bearish reporting a price target of just DKK1300.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $6.3 billion, earnings will come to $1.8 billion, and it would be trading on a PE ratio of 13.2x, assuming you use a discount rate of 5.9%.
Given the current share price of DKK1843.0, the analyst price target of DKK2233.38 is 17.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Genmab?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain